Unknown

Dataset Information

0

Slow-paced respiration therapy to treat symptoms in pulmonary arterial hypertension.


ABSTRACT: To determine the feasibility of using slow-paced respiration therapy to treat symptoms in women with pulmonary arterial hypertension (PAH).People with PAH report increased dyspnea, fatigue and sleep disturbance that can impair health-related quality of life (HRQOL).Ten women with PAH received 8-weeks of daily, 15 min sessions using slow-paced respiration therapy via the RESPeRATE™ device. Participants had baseline and follow up assessments including plasma norepinephrine and interleukin-6 (IL-6), self-report questionnaires to measure dyspnea, fatigue, depressive symptoms, sleep and HRQOL along with 7-day actigraphy and sleep diaries.The mean age was 50 years. Adherence to the intervention was 92%. There was decrease in median IL-6 levels [1.3 ± 0.5 to 1.1 ± 0.4, 95% CI (0.03-0.43)] over the study period. Sleep disturbance decreased, depressive symptoms decreased and HRQOL scores decreased (higher scores indicate worse HRQOL).In this pilot study, slow-paced respiration therapy is feasible in patients with PAH and may improve symptoms and lower IL-6.

SUBMITTER: Matura LA 

PROVIDER: S-EPMC5167631 | biostudies-literature | 2017 Jan - Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Slow-paced respiration therapy to treat symptoms in pulmonary arterial hypertension.

Matura Lea Ann LA   Fargo Jamison J   Fritz Jason S JS   Smith Kerri A KA   Vaidya Anjali A   Pinder Diane D   Archer-Chicko Christine C   Palevsky Harold I HI   Pack Allan I AI   Sommers Marilyn S MS   Kawut Steven M SM  

Heart & lung : the journal of critical care 20161122 1


<h4>Objective</h4>To determine the feasibility of using slow-paced respiration therapy to treat symptoms in women with pulmonary arterial hypertension (PAH).<h4>Background</h4>People with PAH report increased dyspnea, fatigue and sleep disturbance that can impair health-related quality of life (HRQOL).<h4>Methods</h4>Ten women with PAH received 8-weeks of daily, 15 min sessions using slow-paced respiration therapy via the RESPeRATE™ device. Participants had baseline and follow up assessments inc  ...[more]

Similar Datasets

2003-11-15 | GSE703 | GEO
| S-EPMC4418033 | biostudies-literature
| S-EPMC3729596 | biostudies-literature
| S-EPMC5798685 | biostudies-literature
| S-EPMC3614127 | biostudies-literature
| S-EPMC6351343 | biostudies-literature
2014-11-14 | E-GEOD-53408 | biostudies-arrayexpress
| S-EPMC8479804 | biostudies-literature
| S-EPMC5933637 | biostudies-other
2020-09-07 | PXD015896 | Pride